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Abstract EphB4 and its cognitive ligand ephrinB2 play
an important role in embryonic vessel development and
vascular remodeling. In addition, several reports suggest
that this receptor ligand pair is also involved in pathologic
vessel formation in adults including tumor angiogenesis.
Eph/ephrin signaling is a complex phenomena character-
ized by receptor forward signaling through the tyrosine
kinase of the receptor and ephrin reverse signaling through
various protein–protein interaction domains and phos-
phorylation motifs of the ephrin ligands. Therefore, inter-
fering with EphR/ephrin signaling by the means of targeted
gene ablation, soluble receptors, dominant negative
mutants or antisense molecules often does not allow to
discriminate between inhibition of Eph/ephrin forward and
reverse signaling. We developed a speciﬁc small molecular
weight kinase inhibitor of the EphB4 kinase, NVP-
BHG712, which inhibits EphB4 kinase activity in the low
nanomolar range in cellular assays showed high selectivity
for targeting the EphB4 kinase when proﬁled against other
kinases in biochemical as well as in cell based assays.
Furthermore, NVP-BHG712 shows excellent pharmacoki-
netic properties and potently inhibits EphB4 autophos-
phorylation in tissues after oral administration. In vivo,
NVP-BHG712 inhibits VEGF driven vessel formation,
while it has only little effects on VEGF receptor (VEGFR)
activity in vitro or in cellular assays. The data shown here
suggest a close cross talk between the VEGFR and EphR
signaling during vessel formation. In addition to its
established function in vascular remodeling and endothelial
arterio-venous differentiation, EphB4 forward signaling
appears to be an important mediator of VEGF induced
angiogenesis since inhibition of EphB4 forward signaling
is sufﬁcient to inhibit VEGF induced angiogenesis.
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Introduction
Formation of the vascular network is tightly controlled by a
variety of growth factors and their appropriate receptors.
Thus, receptor tyrosine kinases which are expressed on
endothelial cells (ECs) have been shown to be crucial for
embryonic vasculogenesis and angiogenesis (for review see
[1]). While VEGF (vascular endothelial growth factor)
receptors activated by VEGF mainly contribute to very
early steps of vasculogenesis and angiogenesis including
differentiation of EC precursors and formation of a prim-
itive vascular network, two other receptor tyrosine kinases
and their ligands, namely the angiopoietin/TIE-2 (tyrosine
kinase with Ig like loops and EGF like repeats 2) and
ephrinB2/EphB4 respectively, contribute to later steps of
vascular development like vessel branching and vessel
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The Eph receptors (receptor cloned from erythropoietin-
producing hepatocellular carcinoma) are the largest sub-
family of receptor tyrosine kinases and are activated by
their cell surface bound ligands of the equally large ephrin
family (Eph receptor interacting protein). Both, receptors
and ligands are divided into an A- and B-class; nine EphA
receptors bind to ﬁve A-ligands and ﬁve EphB receptors
bind to three ephrinB ligands. Like for other receptor
tyrosine kinases (RTKs), receptor signaling is initiated by
oligomerization and tyrosine-phosphorylation of the
receptor. Unlike other ligand/RTK pairs, also ephrin
ligands can transmit signals upon receptor engagement, a
phenomenon which is called bi-directional signaling.
EphrinB-ligands, which possess a transmembrane and
cytoplasmatic domain, get tyrosine-phosphorylated upon
receptor binding which induces ephrin reverse signaling in
addition to the receptor forward signaling (for review see
[2]). Although quite promiscuous interactions between
EphRs and their ligands the ephrins have been observed,
ephrinB2 is the only known ligand for EphB4. EphB4 and
ephrinB2 were the ﬁrst genes discovered to be differen-
tially expressed in arterial and venous endothelium and
genetic ablation of either EphB4 or ephrinB2 are embry-
onic lethal due to impaired vascular remodeling and arrest
of endothelial differentiation [3, 4].
Over-expression of EphB4 has been reported for several
tumor types including breast, colon, bladder, endometrium
and ovary [5–10]. The role of EphB4 in cancer is not fully
elucidated. On the one side, EphB4 expressed on tumor
cells can interact with ephrinB2 of the endothelium and
thereby promotes tumor angiogenesis and growth [11], on
the other hand EphB4 has been described to either promote
or suppress tumor growth, depending on the tumor type and
tumor model which has been looked at [5, 12–15]. The
paradoxes of EphB4 signaling in cancer has been recently
discussed [16].
Despite this, EphB4 and ephrinB2 signaling has been
proven to be involved in sites of adult angiogenesis by the
use of soluble EphB4 [17, 18]. In addition, monoclonal
inhibitory antibodies and peptides, blocking EphB4-eph-
rinB2 interaction have been developed to study the role of
EphB4/ephbrinB2 signaling [19–21]. Further tools which
have been developed in the context of EphB4/ephrinB2
signaling include engineered mouse models [3, 4, 22, 23],
soluble receptors [5, 17, 24] and peptides blocking ligand
receptor interaction [19, 20].
Small molecule inhibitors of the EphB4 kinase have
been described recently by others with different degree of
speciﬁcity against other kinases [25–28]. So far, no efﬁcacy
data from in vivo studies for these compounds have been
reported. In our studies we noticed, that soluble EphB4
receptor inhibits angiogenesis in a VEGF driven in vivo
model, which has been used to characterize small molecule
inhibitors of the VEGFR2 kinase [29]. Therefore, we tested
whether the selective inhibitor of the EphB4 kinase NVP-
BHG712 would mimic the effect of soluble EphB4 in this
VEGF driven angiogenesis model. To our knowledge, this
is the ﬁrst report demonstrating that a selective small
molecule kinase inhibitor of the EphB4 kinase is sufﬁcient
to inhibit VEGF driven angiogenesis in vivo.
Methods
Synthesis of NVP-BHG712
Synthesis of NVP-BHG712 was performed in the labora-
tories of Novartis Institutes for Biomedical Research and
has been described in the patent application WO2007/
062805 [30].
In vitro kinase assays
All in vitro kinase assays were performed with recombi-
nant puriﬁed kinases either purchased from external ven-
dors or produced in house. To estimate kinase activity both,
TR-FRET-based LanthaScreen
TM
and Caliper mobility shift
were used. The assays have been described previously
[31, 32].
In brief, the LanthaScreen
TM
assay technology is based on
the discrimination between the unphosphorylated substrate
and the phosphorylated product by a phospho-speciﬁc
antibody, binding only to the phosphorylated version of the
substrate. Both, antibody and substrate, carry ﬂuorescent
labels and the close proximity of the labels in the formed
complex allows the measurement of a ﬂuorescence reso-
nance energy transfer (FRET) signal. Reading of the FRET
signal in a time-dependent/time-gated manner further
improves the assay performance by reducing background
ﬂuorescence [33]. For dose–response measurements NVP-
BHG712 was pre-diluted in 90% DMSO and 50 nL of
compound solutions were dispensed directly into the empty
assay plate using a HummingBird nanodispenser (Zinsser
Analytic). The kinase reactions were started by addition of
4.5 lL ATP solution (4 lM ATP, 20 mM Tris/HCL, 1 mM
DTT, 0.03% Tween20, 0.01 mM Na3VO4) and 4.5 lL
enzyme/substrate mix (100 nM ﬂuorescein poly-GAT;
Invitrogen), 0.5% bovine serum albumin, 20 mM Tris/
HCL, 1 mM DTT, 0.03% Tween20, 0.01 mM Na3VO4).
Further components of the enzyme/substrate mix were the
enzymes as well as MgCl2/MnCl2 which were adjusted
speciﬁcally to the requirements of the individual enzyme.
After incubation for 60 min at r.t. the kinase reactions were
stopped by addition of 4.5 lL stop solution (50 mM EDTA
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123pH 8.0, 0.04% NP-40, 20 mM Tris/HCl pH 7.4) followed
by 4.5 lL of detection mix (1.72 lg/mL Tb-PY20 anti-
body; Invitrogen), 1% bovine serum albumin, 20 mM Tris/
HCl, 1 mM DTT, 0.03% Tween20, 0.01 mM Na3VO4).
After incubation for 45 min at r.t. plates were analyzed in a
BMG PHERAstar plate reader (BMG Labtech).
In the Caliper mobility shift assays kinase reactions were
analyzed by microﬂuidic capillary electrophoresis. The
transfer of phosphate from ATP to a short peptide by a
kinase causes a change in the net-charge of the peptide by
-2. The charge difference between the unphosphorylated
andphosphorylatedentitiesofthepeptidecanbeseparatedin
anelectricalﬁeld.Usingpeptidesattachedwithaﬂuorescent
label allows detection and quantiﬁcation of both forms and
hence the calculation of the reaction turnover. For dose–
response measurements NVP-BHG712 was pre-diluted in
90% DMSO and 50 nL aliquots of solution were dispensed
directly into the empty assay plate using a HummingBird
nanodispenser(ZinsserAnalytic).Thekinasereactionswere
startedbyadditionof4.5 lLsubstratemixconsistingofATP
andpeptidesubstrateinassaybuffer(50 mMHEPESpH7.5,
0.02%bovineserumalbumin,1 mMDTT,0.02%Tween20,
0.01 mM Na3VO4, 10 mM beta-glycerophosphate) and
4.5 lL enzyme solution in assay buffer. The peptide con-
centration was 2 lM in the assays. Concentrations for the
enzyme, as well as for MgCl2 and MnCl2 were adjusted
speciﬁcally to the requirements of the individual enzyme.
ATP concentrations were adjusted to the KM values of the
speciﬁc enzyme. After incubation for 60 min at 30C the
kinase reactions were stopped by addition of 16 lL stop
solution(100 mMHEPESpH7.5,5%DMSO,0.1%coating
reagent(CaliperLifescience)10 mMEDTApH8.0,0.015%
BRIJ35). Stopped kinase reactions were analyzed in a
LC3000 reader (Caliper Lifescience).
Autophosphorylation of transient expressed Eph
receptors
Human cDNAs encoding the full length human EphA2,
EphA3, EphB2, EphB3 and EphB4 sequence were cloned
into pCDNA3.1 expression plasmids (Invitrogen). A C-ter-
minal V5-tag (Invitrogen) was introduced into the cDNA of
EphA1, A2, B2 and B3, the cDNA of EphB4 was
C-terminal fused with a myc-epitope. For expression of the
different EphRs Hek293 human embryonic kidney epithe-
lial cells (ATTC No CRL-157) were transiently transfected
using FuGENE 6 transfection reagent (Roche) following
the protocol provided by the vendor. Autophosphorylation
of EphRs receptors was either initiated by the addition of
soluble ephrinA1-Fc (1 lg/ml, R&D Systems; EphA2,
EphA3) or by the addition of a mixture of soluble eph-
rinB1-Fc and soluble ephrinB2-Fc (1 lg/ml each, R&D
Systems; EphB2, EphB3, EphB4), respectively. EphR
proteins were immunoprecipated using either anti-V5-epi-
tope or anti-myc-epitope antibodies and analyzed by wes-
tern using the mab 4G10 anti-phospho-tyrosine antibody.
Cell based phospho-RTK-ELISA
Activity of cellular receptor tyrosine kinase activity was
assessed by different capture ELISAs. The assays for
VEGFR2, IGF1R and InsR have been described elsewhere
[29, 31].
For the EphB4 cell based ELISA a stable clone of
transfected A375 cells has been generated which over-
express human full length EphB4. Cells were seeded in 96
well plates for 24 h, starved over night in medium lacking
FCS but containing 0.1% BSA and stimulated with soluble
ephrinB2-Fc (1 lg/ml/R&D Systems) for 20 min to
enhance EphB4 autophosphorylation. Cells were lysed in
RIPA buffer and captured on Nunc MaxiSorb plates which
had been coated with soluble ephrinB2-Fc (100 ng/well).
Detection of phosphorylated EphB4 was done by the use of
mab PY20 (anti-phospho-tyrosine antibody) coupled to
alkaline phosphatase (ZYMED, Cat Nr 03-7722) diluted
1:5000. After washing (39 with PBS) bound PY20 was
quantiﬁed by the addition of 0.1 ml substrate buffer and
measuring the OD at 405 nm after about 30 min until
yellow color appeared.
Pharmacokinetic analysis
Quantiﬁcation of NVP-BHG712 in plasma and tissue was
performed using HPLC/UV. At the allotted times, mice
(4 at each time) were anesthetized by exposure to approxi-
mately 3% v/v isoﬂuorane in medical oxygen and, after
sampling, killed without recovering from anesthetic. Blood
samples were drawn from the vena cava into heparinized
Eppendorf tubes (30 IU/mL) and the plasma prepared from
the blood by centrifugation (10,000 9 g, 5 min.) The tis-
sues were excised weighed and rapidly frozen in liquid
nitrogen. Plasma and tissue samples were stored frozen at
-70C until analysis. Frozen tissues were minced, then
homogenized in an equal volume of ice-cold phosphate
buffered saline (PBS, Sigma P4417) using a Polytron
homogenizer (TP18-10, IKA, Staufen, Germany) keeping
the material cold during the homogenization. Proteins in
plasma or tissue were precipitated by the addition of an
equal volume of acetonitrile. After 20–30 min at room
temperature the protein precipitate was removed by cen-
trifugation (10,000 g, 5 min.). The supernatant was ana-
lyzed immediately by reversed phase HPLC/UV.
Studies concerning pharmacokinetic analysis described
in this report were performed according to animal experi-
mentation license no. 1766, approved by the Basel Stadt
Authorities.
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123Analysis of phosphorylated EphB4 receptor in lung
tissue
For per oral administration to mice the research formula-
tion 1-Methyl-2-pyrrolidone (NMP) and polyethylene
glycol 300 (PEG300) was used. The free bases were for-
mulated by ﬁrst dissolving the substances in NMP and then
diluting with PEG300 to a ﬁnal concentration of 10% v/v
NMP and 90% v/v PEG300, producing clear solutions of
the compounds. The ﬁnal concentration was 5 mg/mL to
deliver 50 mg/kg. Administration volume was 10 mL/kg
body weight.
Isolated lungs were immediately snap frozen in liquid
nitrogen and kept at -80C until further analysis. To
immuno-precipitate EphB4 from lung tissue, one ml of ice
cold lysis buffer was added to one frozen lung lobe and
tissue was with a polytron homogenizer for 20 s. The
homogenate was kept on ice for 1 h to ensure cell lysis and
cellular debris were removed by centrifugation at
2000 rpm for 15 min. Supernatants were mixed with an
equal volume of 2 mM vanadate in PBS and ﬁltered
through a low protein binding glass ﬁber ﬁlter. To remove
proteins which unspeciﬁcally bind to protein A or protein
G, 0.05 ml of protein A/G bead slurry (PIERCE) was
added and lysates were incubated for 1–2 h on a rotating
wheel. Next beads were removed by centrifugation (3 min
at 5000 rpm) and supernatants were transferred to fresh
tubes. Protein content was estimated using the BCA protein
assay kit (PIERCE) following the instructions of the sup-
plier. For immuno-precipitation of EphB4 0.5 mg of lung
protein was used. 0.5 lg of the corresponding antibody
(goat anti-mouse EphB4 antibody; R&D) was added and
incubated on a rotating wheel for 2 h or over night. Next
10 ll of protein A/G beads were added and incubated for
another hour on a rotating wheel. Protein A/G beads were
span down and washed twice with ice cold PBS supple-
mented with 0.5 mM vanadate. PBS was carefully
removed. 25 ll of SDS sample buffer was added, the
samples were heated for 3 min at 95C and proteins were
separated on 7.5% SDS–PAGE.
In vivo growth factor-induced angiogenesis model
VEGF-mediated angiogenesis in vivo was induced in a
growth factor implant model in mice as described previ-
ously [29, 34, 35]. In this model VEGF is delivered from an
agar chamber which is implanted sub-cutaniously. VEGF
increases dose dependently the amount of newly formed
tissue around the chamber. In previous studies we have
shown that the amount of adherent, vascularized tissue
growing around the chambers and the amount of blood
vessels in this newly formed tissue assessed by either
hemoglobin (converted to equivalents of blood), and Tie-2
content (number of endothelial cells and therefore vessel
density) is blocked by antibodies that speciﬁcally neutral-
ize VEGF or by VEGFR tyrosine kinase inhibitors.
Studies concerning the VEGF driven angiogenesis
model described in this report were performed according to
animal experimentation license no. 1325, approved by the
Basel Stadt Authorities.
Results
Kinase inhibitor proﬁle of NVP-BHG712
Design of NVP-BHG712 was supported by molecular
modeling of the kinase domain of EphB4 and further
optimized using structure-activity-relationship data based
on inhibition of EphB4 autophosphorylation in a cellular
assay. For this a capture ELISA has been developed uti-
lizing stable transfected A375 melanoma cells over-
expressing human full length EphB4 receptor fused to a
myc-epitope at the C-terminal end of the protein. A375
melanoma cells were chosen, because endogenous levels of
EphB4 are nearly undetectable and expression of either
soluble EphB4 or full length EphB4 did not interfere with
cell growth in previous experiments [17]. Selectivity of
NVP-BHG712 was demonstrated in a panel of more than
40 biochemical in vitro kinase assays as well as three other
cell based ELISA assays for RTK autophosphorylation
(Fig. 1). In the biochemical assay panel, only c-raf, c-src
and c-abl were identiﬁed as potential off-targets. In the cell
based ELISA assays for phosphorylated RTKs, marginal
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EphB4 25 (n=8)
VEGFR2 4200 (n=3)
IGF1R >10.000 (n=3)
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kinase IC50 (nM)
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Fig. 1 Structure and selectivity proﬁle of NVP-BHG712. NVP-
BHG712 has been optimized as a speciﬁc inhibitor of the EphB4
kinase in cell based assays measuring different receptor tyrosine
kinases (RTKs) as described in the material and method chapter. The
compound has been further proﬁled in various biochemical kinase
assays as indicated
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123inhibition of VEGFR2 was observed (ED50 = 4200 nM)
while ED50 for EphB4 inhibition in this format was esti-
mated be 25 nM, demonstrating that NVP-BHG712 clearly
discriminates between VEGFR and EphB4 inhibition.
NVP-BHG712 is highly potent in EphR
autophosphorylation cell based assays
To demonstrate the inhibitory activity of NVP-BHG712 in
cell based assay, we also transiently transfected different
EphRs in Hek293 cells. For analysis of EphR autophos-
phorylation we immuno-precipitated the different receptor
proteins and analyzed tyrosine phosphorylation of the
receptors with generic anti-phospho-tyrosine antibodies.
Basal levels of EphR autophosphorylation was observed
for all the EphRs which have been transfected, but was
further enhanced by the addition of the appropriate ligand
(Fig. 2). Addition of NVP-BHG712 dose dependently
inhibited autophosphorylation of the EphRs, showing some
preference for EphB4 followed by inhibition of EphB2,
EphA2, EphB3 and EphA3. Half maximal inhibition of
EphB4 autophosphorylation was in the low nanomolar
range and conﬁrmed data obtained by the ELISA using
stable transfected A375 (see Fig. 1).
NVP-BHG712 has excellent pharmacokinetic
properties and inhibits EphB4 autophosphorylation
in lung tissue
To explore the use of NVP-BHG712 in animal studies we
performed pharmacokinetic/pharmacodynamic studies in
mouse lung tissue. Oral administration of NVP-BHG712
showed a long lasting exposure of parent compound in
plasma as well as in different tissues (Fig. 3b). Concen-
trations around 10 lM were observed in lung and liver
tissue for up to 8 h upon administration of 50 mg/kg of
NVP-BHG712, exceeding far the IC50 for EphB4 inhibi-
tion. EphB4 is expressed in many tissues including lung
and liver and co-expression of EphB4 and ephrinB2 has
been observed in lung tissue on RNA as well as on protein
levels (data not shown). Thus it is not surprising to detect
autophosphorylated EphB4 receptors in lung tissue
(Fig. 3a), although a physiological role for EphB4/eph-
rinB2 signaling in lung tissue has not be described so far.
As expected, NVP-BHG712 inhibited EphB4 autophos-
phorylation in lung tissue. Parallel analysis of phospho-
levels of EphB4 and tissue concentration of NVP-BHG712
Fig. 2 NVP-BHG712 inhibits multiple Eph receptor kinases in cell
based assays. Different EphR full length cDNAs have been transiently
expressed in Hek293 cells. EphR autophosphorylation has been
initiated by stimulating cells for 30 min with either 1 lg/ml
ephrinA1-Fc (EphA2, EphA3) or a combination of 1 lg/ml eph-
rinB1-Fc and 1 lg/ml ephrinB2-Fc. NVPBHG712 was added 1 h
prior cell stimulation and autophosphorylation was monitored by
immuno-precipitation of EphR protein followed by western analysis
using anti-phospho-tyrosine antibodies
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Fig. 3 NVP-BHG712 inhibits endogenous EphB4 autophosphoryla-
tion in lung tissue of mice and has micromolar exposure in plasma
and tissues. NVP-BHG712 has been dosed orally in mice (50 mg/kg).
Mice have been sacriﬁced at time points after oral compound
administration as indicated. a To monitor NVP-BHG712 concentra-
tion and EphB4 autophosphorylation in lung tissue, one lung lobe
were lysed for western analysis and the other lung lobe was used for
pharmacokinetic analysis. EphB4 protein was immuno-precipitated
from lung tissue lysates and analyzed by western using anti-phospho-
tyrosine antibodies. Membranes were stripped and reprobed with a
speciﬁc anti-EphB4 antibody to ensure equal protein loading.
Corresponding NVP-BHG712 concentrations are indicated below
each lane. b NVP-BHG712 concentrations in plasma (ﬁlled circle),
lung tissue (ﬁlled square) and liver tissue (open circle) were analyzed
by HPLC–UV as described in the material and method chapter
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123in the lung revealed that approximately 1 nmol/g (equiv-
alent to 1 lM) was sufﬁcient to have a pronounced
inhibitory effect on EphB4 phosphorylation (Fig. 3a).
From these analyses we concluded that a once daily oral
dosing of 50 mg/kg NVP-BHG712 results in a long lasting
inhibition of EphB4 kinase activity in mice.
Inhibition of EphB4 forward signaling inhibits VEGF
driven angiogenesis
The role of EphB4/ephrinB2 signaling in angiogenesis of
the developing embryo as well as in tumor growth has been
demonstrated by many groups [4, 11, 17, 36]. Soluble
EphB4 receptor protein has been used in a variety of
studies to inhibit EphB4/ephrinB2 signaling [17, 18, 24].
Recombinant soluble EphB4 protein potentially has dif-
ferent effects on EphB4/ephrinB2 signaling depending on
whether it is expressed as a fusion protein with the Fc-part
of IgG1 or not. Fc-fused soluble receptors are generally
used to facilitate protein puriﬁcation and to enhance protein
stability in plasma when applied in vivo. In addition, Fc-
fusion proteins form stable dimers due to disulﬁde bonding
of the Fc part of the molecule. Thus, soluble EphB4-Fc
should prevent ephrinB2 from binding to the native
receptors and thereby inhibit EphB4 activation, but it still
might force ephrinB2 protein to dimerize and potentially
elicit some agonistic effects on ephrinB2 reverse signaling.
In order to study the role of EphB4 forward signaling in
angiogenesis we applied soluble EphB4-Fc as well NVP-
BHG712 in an in vivo model of VEGF driven angiogen-
esis, which we had used before to proﬁle other kinase
inhibitors [29, 35]. In this model, VEGF is released from a
Teﬂon chamber ﬁlled with agar mixed with VEGF. Within
4 days newly formed tissue is observed adherent to the
chamber. The amount of tissue (measured as tissue weight)
as well as the vascular density within this newly formed
tissue (as measured by either hemoglobin or Tie2-levels, a
marker of endothelial cells) is dose dependently increased
by VEGF (Fig. 4). Furthermore, tissue formation and
vascularisation around the Teﬂon chamber is signiﬁcantly
inhibited by administration of either inhibitory antibodies
against VEGF or speciﬁc kinase inhibitors of the VEGFR
[29]. Addition of soluble EphB4-Fc together with VEGF
signiﬁcantly inhibited tissue formation as well as tissue
vascularisation (Fig. 4). Since sEphB4-Fc is an antagonist
of EphB4 forward signaling but might still act agonistic on
ephrinB2 reverse signaling, we speculated, that inhibition
of EphB4 forward signaling is sufﬁcient to block VEGF
driven angiogenesis. This assumption was conﬁrmed by the
use of NVP-BHG712. NVP-BHG712 inhibited dose depen-
dently VEGF stimulated tissue formation and vasculariza-
tion in this model. Already at doses of daily 3 mg/kg p.o
administration we observed signiﬁcant inhibition, and daily
administration of 10 mg/kg/kg p.o. was sufﬁcient to
reverse VEGF enhanced tissue formation and vessel
growth (Fig. 5). From our previous pharmacokinetic
Fig. 4 Soluble EphB4-Fc protein inhibits VEGF driven tissue growth
and angiogenesis. Porous Teﬂon chambers were either ﬁlled with
0.5 ml of 0.8% (w/v) buffered agar (white bars), or 0.5 ml of 0.8%
agar containing 2 lg recombinant puriﬁed VEGF (black bars), or
0.5% agar containing a mixture of 2 lg recombinant puriﬁed VEGF
and 20 lg recombinant puriﬁed sEphB4-Fc (grey bars). Chambers
were implanted sub-cutaneously in the ﬂank of FVB mice. The
responses to VEGF and VEGF in combination with sEphB4-Fc were
analyzed 4 days after implantation by measuring tissue weight (a),
blood content (b) and Tie-2 levels (c). Typical chamber explants of
buffer and VEGF controls after 4 days are shown (d). Values are
mean ± SEM. *p\0.05, statistical signiﬁcance of inhibition, Mann–
Whitney Rank Sum Test (n = 6 per group per experiment)
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123studies we can conclude, that tissue as well as plasma
levels of NVP-BHG712 do not exceed 1 lM under these
conditions and thus are far to low to have any inhibitory
effects on VEGFR2 (see Fig. 1). The congruent results by
either inhibiting EphB4 forward signaling using soluble
EphB4-Fc as well as the inhibitory effects of NVP-
BHG712 further strengthen the ﬁnding that EphB4 receptor
forward signaling indeed participates in VEGF driven
angiogenesis.
Discussion
NVP-BHG712 was synthesized based on rational design
and further optimization led to a potent and selective
inhibitor of the EphB4 receptor tyrosine kinase, as dem-
onstrated in cell based assays. In a panel of more than 40 in
vitro kinase assays, NVP-BHG712 showed excellent
selectivity. Only c-raf, c-src and c-abl showed moderate
inhibition as judged from our biochemical assays. In cell
based assays ED50 for inhibition of EphB4 autophospho-
rylation was found to be 25 nM and thereby be roughly 200
fold more potent on EphB4 than on VEGFR2. Inhibitors of
the EphB4 kinase have been described also by others
[25–28] but for none of them modulation of EphB4 activity
in vivo has been reported. Although there exist several
reports demonstrating the involvement of EphB4/ephrinB2
signaling in vessel growth and tumor angiogenesis, evi-
dence is lacking, that a small molecule inhibitor of the
EphB4 kinase is sufﬁcient to inhibit angiogenesis. Most of
the tools which have been applied in previous studies do not
allow discrimination of inhibition of EphB4 forward versus
ephrinB2 reverse signaling. Furthermore, targeted deletion
of the cytoplasmic domain of ephrinB2 in mice as well as
conditional knock out of ephrinB2 suggested an involve-
ment of ephrin reverse signaling in embryonic vessel
development [22, 37]. Here we describe for the ﬁrst time
that a small molecule inhibitor of the EphB4 kinase inhibits
VEGF driven angiogenesis in vivo. From our cell based
assays and pharmacokinetic/pharmacodynamic analysis we
can rule out that inhibition of VEGFR kinase contributes to
the observed in vivo effects of NVP-BHG712. Neverthe-
less, although NVP-BHG712 shows selectivity against
many kinases, it can not discriminate among different Eph
receptor kinases. Complicating matters, EphB4 is not the
only Eph receptor expressed in the endothelium and adja-
cent pericytes. EphrinA1 as well as ephrinB1 and EphA2,
EphB2, EphB3 have been reported to be expressed either on
the endothelium or adjacent pericytes (for review see
[38–40]). Targeted deletion of EphA2, soluble EphA2
receptors, as well as double transgenic mice lacking EphB2
and EphB3 result in inhibition or defective angiogenesis
[38, 41–43]. Thus we can not rule out, that inhibition of
other Eph receptor kinases contribute to inhibition of VEGF
driven angiogenesis. However, our data presented here
strongly suggest a close cross talk between EphR and
VEGFR signaling, and that both signaling pathways are
needed for a coordinated vessel formation. In endothelial
cells, activation of EphR signaling inhibits VEGF and
Angiopoietin induced MAPK activation, presumably due to
activation of the RasGap protein by activated EphRs
[44].While this manuscript was in preparation two inde-
pendent studies demonstrated that ephrinB2 regulates
internalization and signaling of VEGFR2 and VEGFR3 and
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Fig. 5 NVP-BHG712 inhibits VEGF driven tissue growth and
angiogenesis. Porous Teﬂon chambers were either ﬁlled with 0.5 ml
of 0.8% (w/v) buffered agar (white bars), or 0.5 ml of 0.8% agar
containing 2 lg recombinant puriﬁed VEGF (black bars). Mice
carrying chambers containing VEGF were treated orally once daily
with NVP-BGH712 (3, 10 and 30 mg/kg/day p.o.; grey bars). The
responses to VEGF and VEGF together with daily oral dosing of
NVP-BHG712 were analyzed 4 days after implantation by measuring
tissue weight (a), blood content (b) and Tie-2 levels (c). Values are
mean ± SEM. *p\0.05, statistical signiﬁcance of inhibition, Mann–
Whitney Rank Sum Test (n = 6 per group per experiment)
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123VEGF induced embryonic angiogenesis [45, 46]. These
studies demonstrated the involvement of ephrinB2 in ﬁla-
podia formation of the endothelial tip cell in sprouting
vessels which was dependent on the presence of the
c-terminal PDZ domain of ephrinB2 [45]. Since we have
used sEphB4-Fc as a tool we can not completely rule out
that activation of ephrinB2 contributes to the observed
phenotype. Since NVP-BHG712 pheno-copied the effects
of sEphB4-Fc in our model we assume that inhibition of
EphB4 forward signaling is the predominant cause of
inhibition of angiogenesis at least in the model described
here. In summary our data demonstrate for the ﬁrst time,
that speciﬁc inhibitors of EphR kinases are effective
inhibitors of VEGF driven angiogenesis in vivo and thereby
open a new potential avenue to block angiogenesis in dis-
eases such as cancer or inﬂammatory diseases.
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